Sanofi | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (117)

View All

Latest Posts

About This Stock More About This Stock
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets
Article By: ChinaBio® Today
Saturday, February 3, 2024 2:40 PM EDT
Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones.
In this article: SNY, HCM, BNTX, GRCL
Read
More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024
Article By: Tyler Durden
Thursday, January 4, 2024 1:10 AM EDT
More than 140 brands of drugs are going to see their prices hiked heading into the new year
In this article: GSK, PFE, SNY, TAK
Read
Week In Review: Two China Biopharmas Announce Billion Dollar Deals
Article By: ChinaBio® Today
Saturday, October 14, 2023 12:59 PM EDT
MediLink Therapeutics out-licensed global rights for its antibody-drug conjugate candidate to BioNTech in a $1.1 billion agreement. Meanwhile, BioMap formed a collaboration with Sanofi in a deal with potential value of more than $1 billion.
In this article: IMAB, KNTPF, ASPHF, SNY, BNTX Also: AZN, GSK
Read
The Viral “Tripledemic” Opportunity
Article By: Tony Daltorio
Saturday, January 14, 2023 8:36 AM EDT
Between Covid, the flu, and RSV, investors in over-the-counter consumer pharmaceutical companies might be wondering if now is a logical time to up their holdings in the companies that make cold and flu medicines. Let’s take a look.
In this article: AZN, JNJ, SNY, RBGLY, HLN Also: CVS, WBA
Read
Daily Stock Analysis: Sanofi - November 2022 Snapshot
Article By: Fredrik Arnold
Wednesday, November 16, 2022 4:31 AM EDT
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. The company's decided in late 2019 to pull back from the cardio-metabolic market.
In this article: SNY Also: REGN
Read
All Posts

Latest Tweets for $SNY

No tweets yet!

PARTNER HEADLINES

$SNY

Comments Status Updates
There Is Beta In Protalix Stock Due To PRX-102
Paul McGee • 8/28/2020 2:44:13 AM

Isn't that made by Sanofi $SNY?

Protalix BioTherapeutics Pipeline Progress
Harry Goldstein • 8/10/2020 6:01:37 AM

#Protalix clearly has a lot of potential but there's a limited number of people who will need this drug. So the real question is how much of a dent will they put into #Sanofi's market share. $PLX $SNY

Protalix BioTherapeutics Pipeline Progress
Old Time Investor • 8/3/2020 2:23:12 PM

My pleasure. What's more important than how prevalent the disease is, is how much money #Protalix can make on its new drug. It's competitor, #Sanofi ($SNY) makes $1 billion in revenue annually on their drug. Protalix's sounds like a more promising alternative. I'd definitely rate $PLX a buy.

1 to 3 of 3 comments